Thermo Fisher raises 2026 outlook after 12% Q2 revenue growth
Thermo Fisher Scientific posted Q2 2025 revenue of $6.69 billion, a 12% increase year-over-year, fueled by its laboratory products and biopharma services segments. The company subsequently raised its full-year 2026 outlook.
Key Numbers
Thermo Fisher Scientific (NYSE: TMO) reported its second-quarter 2025 financial results, with revenue reaching $6.69 billion, up 12% compared to the same period last year. The performance was driven by strong demand in its laboratory products and biopharma services businesses.
Key Financial Results
| Metric | Q2 2025 | Q2 2024 | Change |
|---|---|---|---|
| Revenue | $6.69B | $5.97B | +12% |
| Net Income | Not yet disclosed | Not yet disclosed | - |
| EPS | Not yet disclosed | Not yet disclosed | - |
Highlights from the Statement
The company attributed the strong growth to increased demand for its laboratory products and biopharma services, which helped revenue exceed expectations.
Future Guidance
Based on Q2 performance, Thermo Fisher raised its full-year 2026 outlook, though specific figures were not provided.
Stock Impact
No immediate stock price reaction was observed following the announcement, but analysts expect a positive sentiment due to the raised guidance.
What This Means for Investors
The raised outlook reflects management's confidence in sustained growth, particularly in lab products and biopharma services. However, investors should await net income and EPS details for a clearer picture.
Frequently Asked Questions
Found this useful? Share it